Wedbush Maintains Neutral on Intellia Therapeutics, Raises Price Target to $17
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsPrice Target
Wedbush analyst David Nierengarten maintains Intellia Therapeutics (NASDAQ:NTLA) with a Neutral and raises the price target from $12 to $17.
Wedbush analyst David Nierengarten maintains Intellia Therapeutics (NASDAQ:NTLA) with a Neutral and raises the price target from $12 to $17.